There are currently 928 clinical trials in Minneapolis, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Minnesota, Hennepin County Medical Center, Abbott Northwestern Hospital and University of Minnesota/Masonic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622
Recruiting
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Register for Updates
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852
Recruiting
This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab may help the immune system fight cancer. Cetuximab blocks growth signals and may prevent the tumor from growing. Participants are put into 3 groups randomly. Each group receives a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: M Health Fairview Clinics and Surgery Center - Minneapolis, Minneapolis, Minnesota
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112
Recruiting
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Research Site, Minneapolis, Minnesota
Conditions: Endometrial Cancer
Register for Updates
Stellate Ganglion Block for PTSD
NCT05169190
Recruiting
Posttraumatic Stress Disorder (PTSD) is a debilitating condition that affects about 15% of Veterans. Current treatments for Veterans with PTSD include medications and psychological therapies that help to process and desensitize to traumatic events. While effective for many, these treatments do not work for all patients, and many may refuse them. Stellate Ganglion Block (SGB), established to treat pain and other conditions, has shown promise for PTSD: early small studies show it may work fast and... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/18/2025
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Post-traumatic Stress Disorder
Register for Updates
Effects of Walking in Greenspace and the Built Environment in Adults With Prediabetes: A Randomized Crossover Trial
NCT06365723
Recruiting
The goal of this randomized crossover trial is to compare the differences in psychological and physiological effects of walking in two different outdoor environments (urban/suburban commercial environments vs. urban/suburban nature areas/preserves) in adults with prediabetes. The main questions it aims to answer are: * Do psychological measures of stress, anxiety, and affect improve more in one type of outdoor environment over the other? * Do physiological measures of stress improve more in one... Read More
Gender:
ALL
Ages:
Between 25 years and 64 years
Trial Updated:
08/18/2025
Locations: Epidemiological Clinical Research Center, Minneapolis, Minnesota
Conditions: PreDiabetes, Heart Rate Variability (HRV), Stress and Anxiety, Stress Biomarkers
Register for Updates
Blue Light Cystoscopy With Cysview® Registry
NCT02660645
Recruiting
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Bladder Cancer
Register for Updates
Strategy for Improving Stroke Treatment Response
NCT05948566
Recruiting
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota
Conditions: Ischemic Stroke
Register for Updates
Endogenous Pain Inhibition Deficiency in Chronic TMD Pain
NCT06617494
Recruiting
Temporomandibular disorders (TMDs) involve a range of conditions with varied causes, affecting a large portion of the U.S. population and posing challenges for diagnosis and management, especially in chronic cases. Despite advances in understanding TMD pathophysiology, the role of central sensitization, particularly deficient endogenous pain inhibition, remains unclear. The conditioned pain modulation (CPM) test, used to assess pain inhibition in chronic TMD pain, has produced inconsistent resul... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/18/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Chronic Temporomandibular Disorders (TMD)
Register for Updates
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
NCT05605093
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Hennepin Healthcare Research Institute (Site 027-001), Minneapolis, Minnesota +2 locations
Conditions: COVID-19
Register for Updates
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502
Recruiting
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. P... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Register for Updates
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
NCT05958342
Recruiting
The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/18/2025
Locations: Hennepin County Medical Center, Minneapolis, Minnesota
Conditions: Trauma, Hemorrhage
Register for Updates
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
NCT06107426
Recruiting
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in real world setting. ABBV-951 (foslevodopa/foscarbidopa) is an approved drug for the treatment of Parkinson's Disease. The main ROSSINI study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Minnesota - Minneapolis /ID# 268121, Minneapolis, Minnesota
Conditions: Parkinson's Disease (PD)
Register for Updates